Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 12/2005

01.12.2005 | Review

Regulatory T cells and tumor immunity

verfasst von: Subhasis Chattopadhyay, Nitya G. Chakraborty, Bijay Mukherji

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 12/2005

Einloggen, um Zugang zu erhalten

Abstract

Central deletion of “self-reactive” T cells has been the textbook paradigm for inducing “self-tolerance” in the periphery and the concept of a role of T cell-mediated suppression in this process has long been controversial. A decisive shift in the opinion on suppressor T cells has lately occurred with the observations of Sakaguchi’s group that linked a class of CD4+CD25+ T cells to the prevention of autoimmunity from neonatal thymectomy in mice. These CD4+CD25+ T cells have been named T regulatory (Treg) cells. They are believed to be selected in the thymus as an anti-self repertoire. Hence they were referred to as natural T regulatory (nTreg) cells. Presently, in addition to their role in autoimmunity, they are believed to exert regulatory function in infection, in transplantation immunity as well as in tumor immunity. In contrast to these nTreg cells, another class of CD4+ Treg cells also exercises regulatory function in the periphery. These Treg cells are also CD4+ T cells and after activation they also become phenotypically CD4+CD25+. They are, however induced in the periphery as Treg cells. Hence, they are termed as induced Treg (iTreg) cells. There are major differences in the biology of these two types of Treg cells. They differ in their requirements for activation and in their mode of action. Nonetheless, evidence indicates that both nTreg cells and iTreg cells are involved in the control of tumor immunity. The question of how to circumvent their regulatory constraints, therefore, has become a major challenge for tumor immunologists.
Literatur
1.
Zurück zum Zitat Gershon RK, Kondo K (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723PubMed Gershon RK, Kondo K (1970) Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 18:723PubMed
2.
Zurück zum Zitat Moller G (1988) Do suppressor T cells exist? Scand J Immunol 27:247PubMed Moller G (1988) Do suppressor T cells exist? Scand J Immunol 27:247PubMed
3.
Zurück zum Zitat Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531CrossRefPubMed Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531CrossRefPubMed
4.
5.
Zurück zum Zitat Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: I. Requirement of Lyt-1 effector cells for oocyte damage after adoptive transfer. J Exp Med 156:156 Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: I. Requirement of Lyt-1 effector cells for oocyte damage after adoptive transfer. J Exp Med 156:156
6.
Zurück zum Zitat Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: II. Requirement of Lyt-1 effector cells in normal female mice for the prevention of oophoritis. J Exp Med 156:1577CrossRefPubMed Sakaguchi S, Takahasi T, Nisizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice: II. Requirement of Lyt-1 effector cells in normal female mice for the prevention of oophoritis. J Exp Med 156:1577CrossRefPubMed
7.
Zurück zum Zitat Sakaguchi S, Fukuma K, Kuribiashi K, Masuda T (1985) Organ specific autoimmunie diseases induced in mice by elimination of T cell subsets. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a subset as possible cause of autoimmunity. J Exp Med 161:72CrossRefPubMed Sakaguchi S, Fukuma K, Kuribiashi K, Masuda T (1985) Organ specific autoimmunie diseases induced in mice by elimination of T cell subsets. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a subset as possible cause of autoimmunity. J Exp Med 161:72CrossRefPubMed
8.
Zurück zum Zitat Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor a-chain (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151PubMed Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor a-chain (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151PubMed
9.
Zurück zum Zitat Berendt MJ, North RJ (1980) T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69CrossRefPubMed Berendt MJ, North RJ (1980) T-cell-mediated suppression of antitumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69CrossRefPubMed
10.
Zurück zum Zitat North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1PubMed North RJ (1985) Down-regulation of the antitumor immune response. Adv Cancer Res 45:1PubMed
11.
Zurück zum Zitat Mukherji B, Wilhelm SA, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136:1888PubMed Mukherji B, Wilhelm SA, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated suppression of in vitro cytotoxic immune response. J Immunol 136:1888PubMed
12.
Zurück zum Zitat Mukherji B, Nashed AL, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol 136:1893PubMed Mukherji B, Nashed AL, Guha A, Ergin MT (1986) Regulation of cellular immune response against autologous human melanoma. II. Mechanism of induction and specificity of suppression. J Immunol 136:1893PubMed
13.
Zurück zum Zitat Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961CrossRefPubMed Mukherji B, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR, Ergin MT (1989) Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med 169:1961CrossRefPubMed
14.
Zurück zum Zitat Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 26:455CrossRef Sakaguchi S (2000) Regulatory T cells: key controllers of immunologic self-tolerance. Cell 26:455CrossRef
15.
Zurück zum Zitat Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki Y, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahasi T (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18CrossRefPubMed Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki Y, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahasi T (2001) Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18CrossRefPubMed
16.
Zurück zum Zitat Piccirillo CA, Shevach EM (2004) Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 16:81CrossRefPubMed Piccirillo CA, Shevach EM (2004) Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol 16:81CrossRefPubMed
17.
Zurück zum Zitat O’Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nature Med 10:801CrossRefPubMed O’Garra A, Vieira P (2004) Regulatory T cells and mechanisms of immune system control. Nature Med 10:801CrossRefPubMed
19.
Zurück zum Zitat Bach JF (2003) Regulatory T cells under scrutiny. Nature Rev Immunol 3:189CrossRef Bach JF (2003) Regulatory T cells under scrutiny. Nature Rev Immunol 3:189CrossRef
20.
Zurück zum Zitat Ehrlich P (1909) Nederlandsch Tijdschrift voor Geneeskunde: Ueber den jetzigne Stand Der Karzinomforchung. Weekblad Jaargang Eerst helft 5:273 Ehrlich P (1909) Nederlandsch Tijdschrift voor Geneeskunde: Ueber den jetzigne Stand Der Karzinomforchung. Weekblad Jaargang Eerst helft 5:273
21.
Zurück zum Zitat Srivastava PK, Old LJ (1988) Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9:78CrossRefPubMed Srivastava PK, Old LJ (1988) Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today 9:78CrossRefPubMed
22.
Zurück zum Zitat Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725CrossRefPubMed Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725CrossRefPubMed
23.
Zurück zum Zitat Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175CrossRefPubMed Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175CrossRefPubMed
24.
Zurück zum Zitat Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 54:187CrossRefPubMed Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 54:187CrossRefPubMed
26.
Zurück zum Zitat Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329CrossRefPubMed Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329CrossRefPubMed
27.
Zurück zum Zitat Marincola FM, Jaffee EM, Hiclin DJ, Ferrone S (2000) Escape of human solid tumors from T cell-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181PubMed Marincola FM, Jaffee EM, Hiclin DJ, Ferrone S (2000) Escape of human solid tumors from T cell-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181PubMed
28.
Zurück zum Zitat Pawlec (2004) Tumor escape from the immune response. Cancer Immunol Immunother 53:843PubMed Pawlec (2004) Tumor escape from the immune response. Cancer Immunol Immunother 53:843PubMed
29.
Zurück zum Zitat Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy; possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844CrossRefPubMed Ahmad M, Rees RC, Ali SA (2004) Escape from immunotherapy; possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53:844CrossRefPubMed
30.
Zurück zum Zitat Anichini A, Vigetti C, Mortini R (2004) The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855CrossRefPubMed Anichini A, Vigetti C, Mortini R (2004) The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53:855CrossRefPubMed
31.
Zurück zum Zitat Whiteside TL (2004) Down-regulation of the z-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865PubMed Whiteside TL (2004) Down-regulation of the z-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 53:865PubMed
32.
Zurück zum Zitat Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1999) Emergence of Th2 type CD4+ T cell response to repetitive stimulation with antigen and antigen presenting cells, in vitro: Implications in designing tumor vaccines. J Immunol 162:5576PubMed Chakraborty NG, Li L, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B (1999) Emergence of Th2 type CD4+ T cell response to repetitive stimulation with antigen and antigen presenting cells, in vitro: Implications in designing tumor vaccines. J Immunol 162:5576PubMed
33.
Zurück zum Zitat Mukherji B, Guha A, Loomis R, Ergin MT (1987) Cell-mediated amplification and down-regulation of cytotoxic immune response against autologous human cancer. J Immunol 138:1987PubMed Mukherji B, Guha A, Loomis R, Ergin MT (1987) Cell-mediated amplification and down-regulation of cytotoxic immune response against autologous human cancer. J Immunol 138:1987PubMed
34.
Zurück zum Zitat Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytolytic response. J Immunol 145:2359PubMed Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE, Mukherji B (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytolytic response. J Immunol 145:2359PubMed
35.
Zurück zum Zitat Mukherji B, Chakraborty NG, Sivanandham M (1990) T cell clones that react against human tumors. Immunol Rev 116:33PubMed Mukherji B, Chakraborty NG, Sivanandham M (1990) T cell clones that react against human tumors. Immunol Rev 116:33PubMed
36.
Zurück zum Zitat Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T cell subset inhibits antigen specific T cell responses and prevents colitis. Nature 389:737CrossRefPubMed Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG (1997) A CD4+ T cell subset inhibits antigen specific T cell responses and prevents colitis. Nature 389:737CrossRefPubMed
37.
Zurück zum Zitat Roncarolo MG, Bachetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68CrossRefPubMed Roncarolo MG, Bachetta R, Bordignon C, Narula S, Levings MK (2001) Type 1 T regulatory cells. Immunol Rev 182:68CrossRefPubMed
38.
Zurück zum Zitat Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T cells response and tumor vaccine induced CTL in human melanoma. Human Immunol 65:794CrossRefPubMed Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B (2004) Regulatory T cells response and tumor vaccine induced CTL in human melanoma. Human Immunol 65:794CrossRefPubMed
39.
Zurück zum Zitat Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumor specific human CD4+ regulatory T cells and their ligands: implications for immunottherapy. Immunity 20:107CrossRefPubMed Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF (2004) Tumor specific human CD4+ regulatory T cells and their ligands: implications for immunottherapy. Immunity 20:107CrossRefPubMed
40.
Zurück zum Zitat Shimizu J. Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211PubMed Shimizu J. Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211PubMed
41.
Zurück zum Zitat Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukine-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128PubMed Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukine-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128PubMed
42.
Zurück zum Zitat Gallimore A, Sakaguchi S (2002) Regulation of tumor immunity by CD25+ T cells. Immunology 107:5CrossRefPubMed Gallimore A, Sakaguchi S (2002) Regulation of tumor immunity by CD25+ T cells. Immunology 107:5CrossRefPubMed
43.
Zurück zum Zitat Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocytes-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocytes responses. J Exp Med 194:823CrossRefPubMed Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocytes-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocytes responses. J Exp Med 194:823CrossRefPubMed
44.
Zurück zum Zitat Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol 2:1 Jones E, Dahm-Vicker M, Simon AK, Green A, Powrie F, Cerundolo V, Gallimore A (2002) Depletion of CD25+ regulatory cells in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunol 2:1
45.
Zurück zum Zitat Wei-Zen W, Morris GP, Kong Yi-chi M (2004) Antitumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73CrossRefPubMed Wei-Zen W, Morris GP, Kong Yi-chi M (2004) Antitumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 53:73CrossRefPubMed
46.
Zurück zum Zitat Tanaka H, Tanaka J, Jorgen K, Shu S (2002) Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207CrossRef Tanaka H, Tanaka J, Jorgen K, Shu S (2002) Depletion of CD4+CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207CrossRef
47.
Zurück zum Zitat Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine rejection antigens. Eur J Immunol 32:3267CrossRefPubMed Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine rejection antigens. Eur J Immunol 32:3267CrossRefPubMed
48.
Zurück zum Zitat Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients inhibit autologous T cell proliferation. J Immunol 168:4272PubMed Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: regulatory T cells from lung cancer patients inhibit autologous T cell proliferation. J Immunol 168:4272PubMed
49.
Zurück zum Zitat Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+D25+ regulatory T cells suppress tumor immunity sensitive to cyclophosphamide which allows immunotherapy in established tumors to be curative. Eur J Immunol 34:336CrossRefPubMed Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+D25+ regulatory T cells suppress tumor immunity sensitive to cyclophosphamide which allows immunotherapy in established tumors to be curative. Eur J Immunol 34:336CrossRefPubMed
50.
Zurück zum Zitat Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171:5931PubMed Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ (2003) CD4+/CD25+ regulatory cells inhibit activation of tumor primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 171:5931PubMed
51.
Zurück zum Zitat Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 20:771CrossRef Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 20:771CrossRef
52.
Zurück zum Zitat Liyanage UK, Moore TT, Joo HG, Tanaka Y, Hermann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756PubMed Liyanage UK, Moore TT, Joo HG, Tanaka Y, Hermann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756PubMed
53.
Zurück zum Zitat Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267PubMed Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267PubMed
54.
Zurück zum Zitat Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606PubMed Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606PubMed
55.
Zurück zum Zitat Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2003) Immunosuppressive regulatory T cells ate abundant in tumor lymphocytes of Hodgkins lymphoma. Blood 103:1755CrossRefPubMed Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA (2003) Immunosuppressive regulatory T cells ate abundant in tumor lymphocytes of Hodgkins lymphoma. Blood 103:1755CrossRefPubMed
56.
Zurück zum Zitat Javia LR, Rosenberg SA (2003) CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85CrossRefPubMed Javia LR, Rosenberg SA (2003) CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85CrossRefPubMed
57.
Zurück zum Zitat Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16:167CrossRefPubMed Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16:167CrossRefPubMed
58.
Zurück zum Zitat Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942CrossRefPubMed Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942CrossRefPubMed
59.
Zurück zum Zitat Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+CD25+ regulatory T cells are overexpressed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444PubMed Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L (2004) Foxp3 expressing CD4+CD25+ regulatory T cells are overexpressed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444PubMed
60.
Zurück zum Zitat Cozzo C, Larkin J III, Caton AJ (2003) Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 171:5678PubMed Cozzo C, Larkin J III, Caton AJ (2003) Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 171:5678PubMed
61.
Zurück zum Zitat Thronton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287CrossRefPubMed Thronton AM, Shevach EM (1998) CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188:287CrossRefPubMed
62.
Zurück zum Zitat Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999) Thymus and autoimmunity: Production of CD25+CD4+ Naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317PubMed Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999) Thymus and autoimmunity: Production of CD25+CD4+ Naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162:5317PubMed
63.
Zurück zum Zitat Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD(+)CD25(+high) regulatory T cell function. J Immunol 169:6210PubMed Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD(+)CD25(+high) regulatory T cell function. J Immunol 169:6210PubMed
64.
Zurück zum Zitat Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger R (2004) Large-scale in vitro expansion of polyclonal human CD4(+) CD25high regulatory T cells. Blood 104:895CrossRefPubMed Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger R (2004) Large-scale in vitro expansion of polyclonal human CD4(+) CD25high regulatory T cells. Blood 104:895CrossRefPubMed
65.
Zurück zum Zitat Thronton AM, Picirillo CA, Shevach EM (2004) Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 24:366CrossRef Thronton AM, Picirillo CA, Shevach EM (2004) Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 24:366CrossRef
66.
Zurück zum Zitat Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172:6519PubMed Thornton AM, Donovan EE, Piccirillo CA, Shevach EM (2004) Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 172:6519PubMed
67.
Zurück zum Zitat Malek TR (2003) The main function of IL-2 is to promote the development of regulatory T cells. J Leukoc Biol 74:961CrossRefPubMed Malek TR (2003) The main function of IL-2 is to promote the development of regulatory T cells. J Leukoc Biol 74:961CrossRefPubMed
68.
Zurück zum Zitat Suri-Payer E, Cantor H (2001) Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+CD25+ T cells. J Autoimmun 16:115CrossRefPubMed Suri-Payer E, Cantor H (2001) Differential cytokine requirements for regulation of autoimmune gastritis and colitis by CD4+CD25+ T cells. J Autoimmun 16:115CrossRefPubMed
69.
Zurück zum Zitat Asseman C, Mauze S, Leach M, Coffman Rl, Powrie F (1999) An essential role for interleukin-10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:995CrossRefPubMed Asseman C, Mauze S, Leach M, Coffman Rl, Powrie F (1999) An essential role for interleukin-10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:995CrossRefPubMed
70.
Zurück zum Zitat Balkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sachs DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502CrossRefPubMed Balkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sachs DL (2002) CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502CrossRefPubMed
71.
Zurück zum Zitat Takahashi T, Tagami T, Yamazuki S, Ueda T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Dominant immunologic self-tolerance by CD4+CD25+ regulatory T cells constitutively expressing CTLA-4. J Exp Med 192:303CrossRefPubMed Takahashi T, Tagami T, Yamazuki S, Ueda T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Dominant immunologic self-tolerance by CD4+CD25+ regulatory T cells constitutively expressing CTLA-4. J Exp Med 192:303CrossRefPubMed
72.
Zurück zum Zitat Read S, Maimstrom S, Powrie F (2000) CTLA-4 plays an essential role in the function of CD4+CD25+ regulatory cells which control intestinal inflammation. J Exp Med 192:295CrossRefPubMed Read S, Maimstrom S, Powrie F (2000) CTLA-4 plays an essential role in the function of CD4+CD25+ regulatory cells which control intestinal inflammation. J Exp Med 192:295CrossRefPubMed
73.
Zurück zum Zitat Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface bound transformation growth factor beta. J Exp Med 194:629CrossRefPubMed Nakamura K, Kitani A, Strober W (2001) Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface bound transformation growth factor beta. J Exp Med 194:629CrossRefPubMed
74.
Zurück zum Zitat Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S (2002) Phenotype localization and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 196:379CrossRefPubMed Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S (2002) Phenotype localization and mechanism of suppression of CD4+CD25+ human thymocytes. J Exp Med 196:379CrossRefPubMed
75.
Zurück zum Zitat Levings MK, Bacchetta R, Schulz U, Roncarolo MG (2002) The role of IL-10 and TGF beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 129:263CrossRefPubMed Levings MK, Bacchetta R, Schulz U, Roncarolo MG (2002) The role of IL-10 and TGF beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 129:263CrossRefPubMed
76.
Zurück zum Zitat Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137PubMed Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167:1137PubMed
77.
Zurück zum Zitat Cederbom L, Hall H, Ivars F (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30:1538CrossRefPubMed Cederbom L, Hall H, Ivars F (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30:1538CrossRefPubMed
78.
Zurück zum Zitat Misra N, Bayry J, Lacroix-demazes S, Kazatcchkine MD, Kaveri SV (2004) Cutting Edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676PubMed Misra N, Bayry J, Lacroix-demazes S, Kazatcchkine MD, Kaveri SV (2004) Cutting Edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676PubMed
79.
Zurück zum Zitat Gett AV, Sallusto F, Lanzavecchia A, Geginat J (2003) T cell fitness determined by signal strength. Nat Immunol 4:355CrossRefPubMed Gett AV, Sallusto F, Lanzavecchia A, Geginat J (2003) T cell fitness determined by signal strength. Nat Immunol 4:355CrossRefPubMed
80.
Zurück zum Zitat Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B (2004) Rescuing melanoma epitope specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunoterapy. J Immunol 173:6017PubMed Mehrotra S, Chhabra A, Chattopadhyay S, Dorsky DI, Chakraborty NG, Mukherji B (2004) Rescuing melanoma epitope specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunoterapy. J Immunol 173:6017PubMed
81.
Zurück zum Zitat North RJ (1982) Cyclophosphamode-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063CrossRefPubMed North RJ (1982) Cyclophosphamode-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063CrossRefPubMed
82.
Zurück zum Zitat North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90PubMed North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90PubMed
83.
Zurück zum Zitat Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T -cells. Cancer Res 48:1671PubMed Berd D, Mastrangelo MJ (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T -cells. Cancer Res 48:1671PubMed
84.
Zurück zum Zitat Michiels J-P H, Reilly RT, Emens LA, Ercollini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immmune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689PubMed Michiels J-P H, Reilly RT, Emens LA, Ercollini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immmune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689PubMed
85.
Zurück zum Zitat Shevach EM (2002) CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389PubMed Shevach EM (2002) CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389PubMed
86.
Zurück zum Zitat Cohn M (2004) Whither T-suppressors: if they did not exist would we have to invent them? Cell Immunol 227:81CrossRefPubMed Cohn M (2004) Whither T-suppressors: if they did not exist would we have to invent them? Cell Immunol 227:81CrossRefPubMed
Metadaten
Titel
Regulatory T cells and tumor immunity
verfasst von
Subhasis Chattopadhyay
Nitya G. Chakraborty
Bijay Mukherji
Publikationsdatum
01.12.2005
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 12/2005
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-005-0699-9

Weitere Artikel der Ausgabe 12/2005

Cancer Immunology, Immunotherapy 12/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.